trending Market Intelligence /marketintelligence/en/news-insights/trending/qzyaurpno4gpe1e8duspyg2 content esgSubNav
In This List

Corindus gets FDA clearance for automation in robotic-assisted surgery platform

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Corindus gets FDA clearance for automation in robotic-assisted surgery platform

Waltham, Mass.-based Corindus Vascular Robotics Inc. said it received the U.S. Food and Drug Administration's 510(k) clearance for a robotic-assisted surgery platform.

The clearance marks the first robotic movement in the technIQ series for the CorPath GRX platform, which is used in heart surgeries.

The software automation feature, called Rotate on Retract, enables the operator to quickly navigate to a targeted area by automatically rotating the guidewire upon joystick retraction.

The FDA approved the device for procedures related to artery diseases.